InSilico Medicine Cayman TopCo (3696.HK) AI-Powered Stock Analysis
See how InSilico Medicine Cayman TopCo scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
3696.HK●HKSE
TechnologySoftware - Infrastructure
HK$38.22
HK$7.28(16.000%)
Hong Kong Market opens in 37h 13m
Advertisement
InSilico Medicine Cayman TopCo (3696.HK)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerInSilico Medicine Cayman TopCo (3696.HK) Stock Overall Grade
InSilico Medicine Cayman TopCo’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to InSilico Medicine Cayman TopCo's overall stock rating.
Forecast
C+Score
57/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
98/100Analyst Consensus
C+Score
50/100InSilico Medicine Cayman TopCo (3696.HK) AI-Powered Stock Analysis
This asset demonstrates Normal performance with an overall Forecast Score of 57/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (98/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each InSilico Medicine Cayman TopCo stock grade, including financials, comparisons, and forecasts.